New Jersey-based Tris Pharma voluntarily recalled three lots of “Infants Ibuprofen Concentrated Oral Suspension USP (NSAID) 50 mg per 1.25 mL” in early December. The nationwide recall effects Walmart, CVS Pharmacy, and Family Dollar stores as some packages may contain high concentrations of ibuprofen.
No reports of adverse events have been received related to the recall, however, higher level of ibuprofen given to infants could result in permanent kidney damage, nausea, vomiting, stomach pain, diarrhea, tinnitus, headache, and gastrointestinal bleeding.
Products Being Recalled
Specific ibuprofen recalls include:
- Walmart — “Equate” label, National Drug Code (NDC) 49035-125-23, lot numbers 00717009A, 00717015A and 00717024A listed on the label.
- CVS — “CVS Health” label, the NCD number 59779-925-23, lot number 00717024A.
- Family Dollar — “Family Wellness” label, the NCD 55319-250-23, lot number 00717024A.
The labels of the recalled products being sold at Walmart included expiration dates of February, April, and August 2019, while the CVS and Family Dollar products expire in August 2019.
What is Ibuprofen?
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, reduce fever and inflammation. Infant ibuprofen is considered safe in infants over three months old who have a body weight exceeding 11 pounds. The correct dosage is based upon weight, not age. Doses can be repeated every six to eight hours, but more than four doses should not be given in a 24 hour period.
In the U.S., ibuprofen’s use is largely confined to infants over six months of age due to safety concerns. Research has not shown a significant increase of adverse gastrointestinal or renal issues in infants younger than six months old compared to those over six months of age who have used the medication. There is, however, much less research on ibuprofen’s use in infants under six months.
Other Dangerous Drugs News
Research suggests Dupixent (dupilumab) may be linked to an increased risk of cutaneous T-cell lymphoma (CTCL). Learn what studies show, how CTCL may be misdiagnosed as eczema, and the legal options for patients diagnosed with lymphoma after taking Dupixent.
Childers, Schlueter & Smith has filed the first Dupixent lawsuit in Georgia, alleging a link between the eczema drug and cutaneous T-cell lymphoma (CTCL). The complaint highlights questions about risk disclosure.
A recent FDA-approved label change now warns of brain meningioma risks linked to Depo-Provera. This update explains what changed, why lawsuits are being filed, and what the warning may mean for women diagnosed with brain tumors.
While Suboxone helps fight opioid addiction, it’s now at the center of a growing legal battle over severe, preventable dental harm not disclosed to patients for years.
Women across the U.S. are filing lawsuits against Pfizer after a major study linked long-term use of Depo-Provera to a fivefold increase in the risk of developing brain tumors known as meningiomas.
Women diagnosed with meningiomas after using Depo-Provera may be eligible for financial compensation, as lawsuits claim Pfizer failed to warn about the potential risk of brain tumors.
